Home/Rare Diseases/Sarcoidosis

Multi-System

Sarcoidosis

Also called sarcoid

Sarcoidosis is a multisystem inflammatory disorder of unknown etiology characterized by non-caseating granuloma formation in affected organs, most commonly the lungs and mediastinal lymph nodes. The disease can affect virtually any organ system including lungs, liver, heart, nervous system, skin, and eyes.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Sarcoidosis

Clinical trials are evaluating immunomodulatory therapies, TNF-alpha inhibitors, and other targeted immune therapies for sarcoidosis. The Sarcoidosis Foundation and patient organizations provide trial information and support.

Try Match Me →

About Sarcoidosis

Sarcoidosis is a multisystem inflammatory disorder of unknown etiology characterized by non-caseating granuloma formation in affected organs, most commonly the lungs and mediastinal lymph nodes. The disease can affect virtually any organ system including lungs, liver, heart, nervous system, skin, and eyes. The pathophysiology involves aberrant immune response to unknown antigen(s), with enhanced Th17 differentiation and granuloma formation. Clinical presentation is highly variable: many patients present with incidental findings on imaging (bilateral hilar lymphadenopathy), while others present with pulmonary symptoms (cough, dyspnea), systemic symptoms (fever, fatigue, arthralgia), or organ-specific manifestations (cardiac arrhythmias, neurological disease, skin lesions). Approximately one-third of patients have self-limited disease that resolves spontaneously; one-third have persistent disease; and one-third develop progressive organ dysfunction. Diagnosis involves clinical and radiological findings plus histological confirmation of non-caseating granulomas.

Common Symptoms

  • Persistent cough and shortness of breath
  • Fatigue and malaise
  • Joint and muscle pain
  • Skin lesions including erythema nodosum and lupus pernio
  • Fever and night sweats
  • Lymphadenopathy and hepatosplenomegaly in some patients

Who It Affects

Can present at any age, typically ages 20-60. Higher incidence in African Americans and Northern Europeans. Women slightly more affected than men. Often diagnosed incidentally on imaging.

Getting Involved in Clinical Trials

Clinical trials are evaluating immunomodulatory therapies, TNF-alpha inhibitors, and other targeted immune therapies for sarcoidosis. The Sarcoidosis Foundation and patient organizations provide trial information and support. Treatment decisions depend on disease extent and organ involvement; many patients with limited pulmonary disease require no treatment. Those with progressive disease may require corticosteroids or immunosuppressive agents. TNF-alpha inhibitors (infliximab, adalimumab) have shown benefit in steroid-refractory disease. Discuss with your pulmonologist or rheumatologist about trial eligibility and optimal treatment strategy based on your organ involvement.

Trusted Sources

Active Clinical Trials for Sarcoidosis

Finding trials for Sarcoidosis...

Related Multi-System Conditions

Multi-System

Tuberous Sclerosis

Tuberous sclerosis is an autosomal dominant genetic disorder caused by mutations in TSC1 or TSC2 genes, resulting in dys...

Multi-System

Epidermolysis Bullosa

Epidermolysis bullosa is a group of rare genetic blistering disorders caused by mutations affecting proteins anchoring t...

Multi-System

Progeria

Progeria is an extremely rare genetic disorder causing rapid aging in children. A single point mutation in the LMNA gene...